杨门女将国语,千禧金瓶梅快播,美乃雀电影在线看

Captodiame

NMR下載 COA and HPLC MSDS下載
names：
Captodiame
CAS號：
486-17-9
MDL Number：
MF(分子式)： C21H29NS2 MW(分子量)： 359.592
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
DBK501876-500mg	500mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00
DBK501876-100mg	100mg		￥ 0.00	￥ 0.00		Get quote	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	Captodiame
英文別名	Captodiame
CAS號	486-17-9
Inchi
InchiKey
分子式 Formula	C21H29NS2
分子量 Molecular Weight	359.592
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions

Captodiame使用注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害。
3.取樣品的移液槍頭需及時更換，必要時為避免交叉污染盡可能選擇濾芯吸頭。
4.稱量藥品時選用稱量紙，并無風處取藥和稱量以免揚撒，試劑的容器使用前務必確保干凈，并消毒。
5.取藥品時盡量采用多個藥勺分別使用，使用后清洗干凈。
6.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染。
大規格定制：定制產品請將信息發送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

產品說明	Benzenoids
Introduction	Based on results obtained from the Pathfinder clinical studies, turoctocog alfa pegol (N8-GP) was shown to provide effective routine prophylaxis in people with severe haemophilia A through a fixed dosing regimen of one injection every 4 days in adults and adolescents, or every 3-4 days (twice-weekly) in children10. Furthermore, N8-GP provided effective prophylaxis and maintained a low median annualized bleeding rate (ABR) of 1.18 when administered at doses of 50 IU/kg every 4 days in adults and adolescents10. Additionally, N8-GP was also found to be efficacious in the treatment and control of bleeding episodes and the perioperative management of bleeding10. Across the clinical trials and age groups, N8-GP was shown to be well tolerated and no safety concerns were identified10. The overall safety profile of N8-GP is similar to what has been reported for other long-action FVIII products10. Moreover, in general, no FVIII inhibitor antibodies have been detected, and no thromboembolic events have occurred with the use of N8-GP4.
Application1	TargetActionsOrganismA5-hydroxytryptamine receptor 2CantagonistHumansASigma non-opioid intracellular receptor 1agonistHumansADopamine D3 receptoragonistHumans
Application2	Inhibitor
Application3